- Redcare Pharmacy reported nine month 2026 sales of €2,549.7 million compared with €2,145.7 million a year earlier, with the net loss narrowing to €5 million from €8.7 million, and confirmed full year 2026 revenue guidance for 16% to 18% growth.
- The combination of higher sales, a smaller loss and unchanged guidance indicates that Redcare Pharmacy is aiming to balance expansion with tighter cost control, while maintaining its stated growth targets.
- This context provides a basis for considering how Redcare Pharmacy’s confirmed 16% to 18% revenue growth guidance may influence its broader investment narrative.
Scan beyond Redcare Pharmacy and compare this guidance-driven story with a curated set of 588 high quality undiscovered gems that pair solid fundamentals with under-the-radar growth ambitions.
Redcare Pharmacy Investment Narrative Recap
To own Redcare Pharmacy, you need to believe that higher digital prescription volumes, better logistics and a richer mix from marketplace and retail media can gradually turn a growing revenue base into sustainable profits. The confirmed 16% to 18% revenue growth guidance reinforces that management is still leaning into expansion.
The key near term swing factor is execution on e prescription adoption and logistics efficiency, while keeping marketing spend under control in weaker non prescription categories. The biggest risk remains regulatory and infrastructure setbacks around e prescriptions in Germany and Europe. This update does not materially change that risk profile.
The confirmation of 2026 revenue growth guidance sits alongside the nine month numbers that showed €2,549.7 million of sales and a net loss of €5 million. That combination points to a business that is still loss making but edging closer to breakeven as it scales. This matters for any thesis built on margin improvement.
For catalysts, the guidance update ties directly into the existing story around Rx growth, logistics automation and higher margin services. It gives investors a concrete near term hurdle to track against those longer term projects, while the persistence of losses keeps execution risk front and centre if marketing, competition or regulation move in the wrong direction.
Redcare Pharmacy's narrative projects €4.5 billion revenue and €99.2 million earnings by 2029. This assumes 12.2% yearly revenue growth and an earnings increase of about €141 million from current earnings, compared with a €42.0 million loss today.
Uncover why Redcare Pharmacy's fair value indicates a 26% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
One alternate view pins everything on Redcare Pharmacy squeezing more earnings out of each customer. The most optimistic analysts were already sketching out about €4.7b in 2029 revenue and €113.8m in earnings before this guidance confirmation. You can compare that richer profit story with today’s update and decide whether those older forecasts still feel realistic.
Explore 6 other Redcare Pharmacy fair value estimates, including one that suggests as much as 407% upside from the current price!
Reach Your Own Conclusion
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Redcare Pharmacy research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Redcare Pharmacy. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Redcare Pharmacy's overall financial health at a glance.
Looking for more investment ideas beyond Redcare Pharmacy?
If Redcare Pharmacy has sharpened your thinking about growth, risk and execution, use that same lens across the wider market with the Simply Wall St Screener and build a shortlist that actually matches your own criteria.
- For investors who want income that does some of the heavy lifting, scan a curated set of 232 dividend fortresses that may help anchor your portfolio.
- If capital preservation sits near the top of your priority list, filter for 212 resilient stocks with low risk scores and focus your attention on companies with lower historical risk scores.
- When the aim is to find strong fundamentals without overpaying, start with a hand picked pool of 224 high quality undervalued stocks and see which businesses fit your return expectations.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com